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Background: Multiple myeloma (MM) is at present an incurable malignancy, characterized by apoptosis-resistant
tumor cells. Interferon (IFN) treatment sensitizes MM cells to Fas-induced apoptosis and is associated with an
increased activation of Signal transducer and activator of transcription (Stat)1. The role of Stat1 in MM has not been
elucidated, but Stat1 has in several studies been ascribed a pro-apoptotic role. Conversely, IL-6 induction of Stat3 is
known to confer resistance to apoptosis in MM.
Methods: To delineate the role of Stat1 in IFN mediated sensitization to apoptosis, sub-lines of the U-266-1970 MM
cell line with a stable expression of the active mutant Stat1C were utilized. The influence of Stat1C constitutive
transcriptional activation on endogenous Stat3 expression and activation, and the expression of apoptosis-related
genes were analyzed. To determine whether Stat1 alone would be an important determinant in sensitizing MM
cells to apoptosis, the U-266-1970-Stat1C cell line and control cells were exposed to high throughput compound
screening (HTS).
Results: To explore the role of Stat1 in IFN mediated apoptosis sensitization of MM, we established sublines of the
MM cell line U-266-1970 constitutively expressing the active mutant Stat1C. We found that constitutive nuclear
localization and transcriptional activity of Stat1 was associated with an attenuation of IL-6-induced Stat3 activation
and up-regulation of mRNA for the pro-apoptotic Bcl-2 protein family genes Harakiri, the short form of Mcl-1 and
Noxa. However, Stat1 activation alone was not sufficient to sensitize cells to Fas-induced apoptosis. In a screening
of > 3000 compounds including bortezomib, dexamethasone, etoposide, suberoylanilide hydroxamic acid (SAHA),
geldanamycin (17-AAG), doxorubicin and thalidomide, we found that the drug response and IC50 in cells
constitutively expressing active Stat1 was mainly unaltered.
Conclusion: We conclude that Stat1 alters IL-6 induced Stat3 activity and the expression of pro-apoptotic genes.
However, this shift alone is not sufficient to alter apoptosis sensitivity in MM cells, suggesting that Stat1
independent pathways are operative in IFN mediated apoptosis sensitization.
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Multiple myeloma (MM) is a malignancy characterized
by an accumulation of plasma cells/ plasma blasts in the
bone marrow. Common complications of MM include
anemia, renal dysfunction, and bone destruction. Con-
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reproduction in any medium, provided the orcorticosteroids, autologous and allogeneic bone marrow
transplantation, bisphophanates, and novel drugs such
as thalidomide, bortezomib, and lenalidomide can im-
prove the quality of life and extend patient survival [1].
However, resistance to therapy often develops, making
MM uniformly fatal.
A biological or mechanistic approach to combat drug
resistance is to delineate the specific factors that are im-
portant in the regulation of growth, apoptosis andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for increased drug efficacy and circumvention of apop-
tosis resistance can be defined [2]. Ideally, therapy could
be individualized based on the expression profile of the
malignant plasma cells of the individual patient.
The aim of this study was to evaluate the importance
of signal transducer and activator of transcription (Stat)
1 in influencing apoptosis and drug resistance in MM.
Stat1 belongs to a family of transcription factors that are
associated with regulation of growth and survival in
hematopoietic cells. Upon cytokine stimulation, these
proteins become phosphorylated by kinases, such as
janus activated kinases (JAKs), associate with the cyto-
plasmic part of the cytokine receptor, form homo- or
heterodimers and, finally, translocate to the nucleus
where they bind to specific DNA elements and directly
regulate transcription [3,4].
The Stat proteins Stat1 and Stat3 are constitutively
activated in several types of tumors [5] including MM
[6,7]. Stat3 is predominantly activated by the MM
growth and survival factor IL-6. Stat1 is mainly activated
by interferons, but can also to some extent be activated
by IL-6 [8]. Stat3 has been defined as an oncogene in
light of its ability to mediate cellular transformation and
block apoptosis [9]. Some downstream targets of Stat3
that have been suggested to mediate these effects are
anti-apoptotic Bcl-2-proteins and cell cycle regulators
i.e. Bcl-XL, Mcl-1, c-Myc, and Cyclins D1/D2 [10]. In
MM, the survival promoting effect of Stat3 has been
ascribed to an up-regulated expression of the anti-
apoptotic Bcl-2 family member Bcl-XL [6]. In contrast
to Stat3, Stat1 has been proposed to promote apoptosis
rather than survival [11-15]. It has been suggested that
the relative abundance of the Stat1 and Stat3 proteins
may influence the activity of each other. Supporting this
hypothesis, Stat3 expression and activation is enhanced
in Stat1 null cells [16] and, conversely, Stat1 expression
and activation is enhanced in Stat3 null cells [17]. In is-
chemia / reperfusion mediated apoptosis, Stat1 was
shown to promote apoptosis by down-regulating the
Bcl-2 and Bcl-XL genes, whereas Stat3 counteracted this
effect by up-regulating these genes [18]. Several inhibi-
tors of Stat3 signaling have been developed (reviewed in
[19]) for anti-cancer therapy, including a hairpin decoy
oligonucleotide. This inhibitor was designed to block
Stat3 but not Stat1 function, thereby presumably avoid-
ing the tumor antagonist effects of Stat1 [20].
We have previously reported that MM cells that
are highly resistant to Fas-induced apoptosis can be re-
sensitized by pretreatment with IFN-γ [21]. One under-
lying cause for this effect was IFN-γ-induced up-
regulation of the Fas receptor (CD95). Interestingly, we
found that in addition to inducing and activating Stat1,
IFN-γ also deactivated Stat3 [22]. In light of thisobservation, we hypothesized that one mechanism of
IFN-γ mediated sensitization to apoptosis was deacti-
vation of anti-apoptotic Stat3, possibly as a conse-
quence of increased transcriptional activation and
expression of Stat1.
To delineate the role of Stat1 in IFN mediated
sensitization to apoptosis induced by Fas and therapeut-
ically relevant drugs, we established sub-lines of the IL-6
dependent MM cell line U-266-1970 with a stable over-
expression of wild type Stat1 as well as its active mutant
Stat1C [23]. The Stat1C was utilized to obtain Stat1
homodimers and transcriptional activation also in the
absence of IFN-γ induced tyrosine phosphorylation. To
determine whether Stat1 alone would be an important
determinant in sensitizing MM cells to apoptosis, the
U-266-1970-Stat1C cell line and control cells were
exposed to high throughput compound screening (HTS).
In addition, we explored the influence of Stat1C consti-
tutive transcriptional activation on endogenous Stat3
expression and activation, and the expression of
apoptosis-related genes.
We report here that constitutive transcriptional activa-
tion of Stat1 in the U-266-1970 MM cell was indeed
associated with an attenuation of Stat3 activation and a
differential expression of several genes involved in apop-
tosis. However, Fas-induced apoptosis was not augmen-
ted in the U-266-1970-Stat1C cells, suggesting that
increased activation of Stat1 transcription alone does
not confer increased sensitization to Fas-induced apop-
tosis in MM. In a high through-put screening (HTS) of
more than 3000 drugs, including bortezomib, dexa-
methasone, etoposide, suberoylanilide hydroxamic acid
(SAHA), geldanamycin (17-AAG), doxorubicin and thal-
idomide, used in conventional and experimental MM
therapy, as well as compounds from two annotated drug
libraries, we found that IC50 was not reduced in U-266-
1970-Stat1C. In fact, for two related agents, gitoxin and
gitoxigenin, Stat1C conferred resistance rather than
increased sensitivity. We conclude that shifting the bal-
ance from Stat3 to activated Stat1 in MM has an impact
on transcriptional activation of genes i.e. Mcl-1, Noxa
and Harakiri, but that this shift alone is not sufficient to
alter sensitivity to IFN mediated apoptosis sensitivity or
general drug response in MM cells.
Methods
Cell culture conditions
The IL-6 dependent MM cell line U-266-1970 [24] was
maintained at 37°C in 5% CO2 in RPMI 1640 medium
(Sigma Biosciences, St Louis, MO) supplemented with
10% heat inactivated fetal bovine serum (FBS; GIBCO,
Grand Island, NY), 2 mM glutamine (Sigma), antibiotics
(penicillin 100 U/mL and streptomycin 50 μg/mL)
(Sigma), and 20 U/mL IL-6 (R&D Systems Europe Ltd,
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medium was also supplemented with G418 (Gibco). The
cells were stimulated with IFN-γ, (1000 U/mL, Bender
MedSystems GnbH, Vienna, Austria) as indicated. Un-
less stated otherwise, IL-6 was always present in the
experiments. The U3A cell line, a Stat1-deficient mutant
of the human fibroblast cell line 2ftgh cell line [25], was
a kind gift from Dr. G.R. Stark. This cell line was main-
tained in Dulbeccos Modified Eagle´s Medium supple-
mented with 10% heat inactivated fetal bovine serum
(FBS; GIBCO, Grand Island, NY), 2 mM glutamine
(Sigma), antibiotics (penicillin 100 U/mL and strepto-
mycin 50 μg/mL) (Sigma). All experiments were per-
formed on exponentially growing cells.
Plasmids for transient and stable Stat1transfections
The wtStat1pcIneo plasmid has been described previ-
ously [26]. The empty pcIneo vector (Promega) was used
as a negative control. The FLAG-tagged STAT1C con-
struct, consisting of a mutated form of Stat1 with Ala-
656 and Asn-658 substituted for cysteine, a FLAG-tag,
and a gene for neomycin resistance, was a kind gift from
Dr. Sironi and Dr. Ouchi [23]. The pcDNA3.1.EGFP vec-
tor expressing green fluorescent protein was used as a
marker for transient transfection (Biosciences).
Transfections
To obtain cells with a stable expression of wtStat1 and
Stat1C in U-266-1970 cells, the cells were nucleofected
using the Amaxa Nucleofector™ apparatus (Amaxa, Co-
logne, Germany) according to the instructions of the
manufacturer. Briefly, 2 x 106 U-266-1970 cells were
grown in cell medium without antibiotics for 24 hours
and were then washed once in cold phosphate-buffered
saline, and resuspended in 100 μl of electroporation buf-
fer R with 4 μg of wtStat1pcIneo, empty pcIneo vector,
or Stat1C vector as indicated. The cell suspension was
the transferred to a 2.0 mm electroporation cuvette, and
nucleofected with an Amaxa Nucleofector™ apparatus
using nucleofection program U-05. 24 hours post-
transfection IL-6 (20 U/ml) and G418 (1000 μg/ml) was
added to the medium to select for stably transfected
cells. After 6–10 weeks G418-resistant cells were main-
tained in cell medium with IL-6 (20 u/ml) and G418
(500 μg/ml).
For transient transfections of adherent U3A cells and
2ftgh, the calcium phosphate transfection method was
used. Briefly, 6 x 106 cells were seeded in each 10 cm
plate the day before transfection. Chloroquine dispho-
sphate was added 30 minutes before transfection to the
cell culture plates. DNA (10 μg) was mixed with 0.25 M
CaCl2. The mixture was then added to an equal volume
of 2x HEPES-buffered saline, incubated for 20 minutes
and finally added to the cells. The medium was changedand IFN-γ was added 6 hour post-transfection. The cells
were harvested after 24 hours of IFN-γ stimulation.PCR
For identification of stably transfected cells expressing
pcIneo and wtStat1 pcIneo, PCR was performed with
forward primer 5’-AAG GCT AGA GTA CTT AAT
ACG-3’ and reverse primer: 5’-ATT AAC CCT CAC
TAA AGG GA-3’ (program:: 95° 7 min, (95° 25 s, 55°
25 s, 72° 30 s)x40, 72° 2 min). The reactions were per-
formed using the Platinum Taq polymerase (Invitrogen)
according to the manufacturer’s protocol.Western blot
U-266-1970 cells were incubated with 20 U/mL IL-6
alone or in combination with 1000 U/mL IFN-γ for the
indicated time periods followed by harvest. For whole
cell protein extracts, cells were washed once in PBS and
lysed in 1% NP40, 0.1 M Tris–HCl, 0.15 M NaCl, 5 mM
EDTA with protease inhibitors (1 mM ZnCl2, 50 mM
Na2MoO4, 10 mM NaF, 0.1 mM NaVO3, 1 mM PMSF,
1 mM DTT, 1 x complete, EDTA-free (Roche, Mann-
heim, Germany) for 20 minutes at 4°C and centrifuged
for 10 minutes at 4°C at 10000 X g to remove cellular
debris. The supernatant was collected and the protein
concentration was measured using the Bio-Rad protein
assay (Bio-Rad Laboratories, Hercules, CA). After heat-
ing the samples at 70°C for 10 minutes the protein
extracts were fractionated on NuPAGE Bis-Tris pre-cast
gels (4-12%, 10%, 12%) using the Novex electrophoresis
and blotting system (NOVEX, San Diego, CA). The
membrane (Hybond-C extra, Amersham, United King-
dom) was blocked in 5% non-fat milk in TTBS (20 mM
Tris–HCl (pH 7,5), 500 mM NaCl, and 5% Tween 20) at
room temperature for 1 h, and then incubated at 4°C
overnight with primary antibodies diluted in TTBS + 5%
non-fat milk. The membrane was then washed 5x5 min-
utes in 1xTTBS, and incubated with secondary horserad-
ish peroxidase (HRP)-linked antibodies (Amersham or,
for detection of Stats and actin, DAKO, Glostrup, Den-
mark) diluted in TTBS+ 5% non-fat milk for 1 hour at
room temperature. After washing 5x5 minutes in
1xTTBS, protein detection by enhanced chemi-
luminescence (ECL plus; Amersham, Bucks, U.K) was
performed according to the manufacturer's protocol. Pri-
mary antibodies used where α-Bcl-xL (H-62), α-Bcl-2
(C-21), α-actin (I-19), α-Stat1 (C-111), α-Stat3 (C-20), α-
Mcl-1 (S-19), α-IRF-1 (C-20), α-Noxa (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), anti-Fas (UB2,
Immunotech, Marseilles, France), anti-Histon H3
(ab1791) (abcam), anti-α-tubulin (A11126) (Invitrogen),
rabbit polyclonal α-pStat1, rabbit polyclonal α-pStat3
(New England Biolabs, Beverly, MA, USA), α-FLIP (804-
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land), and α-FLAG (F-1804) (Sigma).
Nuclear protein lysates
U-266-1970-Stat1C, and U-266-1970-pcIneo cells were
incubated with IL-6 (20 U/mL) for 24 hours and were
then stimulated with IL-6 alone or in combination with
1000 U/mL IFN-γ for the indicated time points. Nuclear
and cytoplasmic protein lysates were prepared essentially
as described by Andrews and Faller [27].
Luciferase reporter assay
By using the Amaxa system as described, U-266-1970-
pcIneo and U-266-1970-Stat1C cells were transiently
transfected with 3 μg of the GBP-luc reporter vector (a
kind gift from Dr. B. Lüscher, Hannover). The GBP-luc
vector contains a luciferase reporter gene driven by a
fragment of the human guanylate binding protein pro-
moter containing Stat1-inducible ISRE and GAS ele-
ments [28]. To normalize the luciferase values due to
differences in transfection efficiency, the cells were co-
transfected with 1 μg of the vector hubactp/lacZ vector.
This vector, which contains 4 kb of the human β-actin
promoter linked to a lacZ reporter gene, was kindly pro-
vided by Dr. U. Lendahl [29]. Luciferase activity was
measured in a luminometer (Lumat LB9501EG&G, Bert-
hold, MA) using Luciferase Assay Reagent (Promega)
according to manufacturer’s protocol. B-galactosidase ac-
tivity was measured in the same luminometerusing
Galacton and Emerald reagents (TROPIX; Bedford, USA)
according to manufacturer’s protocol.
Multiplex Ligation-Dependent Probe Amplification Assay
(MLPA)
MLPA is a mRNA quantification assay based on probes,
each of which consists of two unique oligonucleotides of
specific lengths, one unlabeled and one fluorescently la-
beled, that anneal to adjacent sites on a specific target
sequence. The annealed probes are ligated, allowing
amplification of target sequences with specific lengths
that can be quantified by capillary sequence analysis. All
the probes used in the apoptosis gene probe set and
detailed protocols have been described elsewhere
[30,31]. U-266-1970-pcIneo and U-266-1970-Stat1C
were incubated with 20 U/mL IL-6 (R&D Systems Eur-
ope Ltd, Abington, UK) alone or in combination with
1000 U/mL IFN-γ. The cells were harvested after 6 h
and total RNA was prepared by Trizol extraction (Invi-
trogen) according to the manufacturer’s recommenda-
tion. Any contaminating DNA was removed using DNA-
free™(Ambion). The MLPA was performed using the
SALSA P011 Apoptosis mRNA MLPA kit (MRC-Hol-
land , Amsterdam, The Netherlands) according to manu-
facturer’s recommendations. Briefly, 100 ng of RNA wasfirst reverse transcribed using MMLV reverse transcript-
ase (Promega) together with the SALSA RT buffer and
the SALSA RT primer mix. The resulting cDNA was
hybridized to the SALSA probemix. Hybridized oligos
were subjected to a ligation reaction, and ligation pro-
ducts were amplified by PCR using one labeled and one
FAM-labeled primer. PCR products were analyzed on
the ABI3700 capillary sequencer (Applied Biosystems)
and peak areas representing gene expression was calcu-
lated using GeneScan software (ver3.7) for each gene.
Data was normalized using the control gene ß-2 micro-
globulin, then all peak areas were summed to 100% and
the relative peak area for each gene was calculated from
this.Resazurin assay
Resazurin is the active compound of the commercially
available compound Alamar Blue [32]. The resazurin
assay can be used to quantify cell proliferation and cyto-
toxicity since the substance becomes increasingly fluor-
escent in the presence of metabolically active cells [33].
U-266-1970-pcIneo and U-266-1970-Stat1C were incu-
bated with 20 U/mL IL-6 (R&D Systems Europe Ltd,
Abington, UK) alone or in combination with 1000 U/mL
IFN-γ in round bottomed 96-well plates. After the indi-
cated time points, 10% Alamar Blue (resazurin) (Serotec
Limited, Oxford, UK) was added to the wells, followed
by incubation for 3 h at 37°C in a humidified 5% CO2
in-air atmosphere. The resazurin assay was also used to
confirm the response to drugs identified in the high
throughput FMCA screening. Analysis of fluorescence
was performed by using a Wallac Victor Multilabel
Counter (Wallac, Turku, Finland), where the resazurin
was excited at 530 nm and the emitted light was mea-
sured at 590 nm. Mean was calculated from triplicate
wells and subtracted from mean of blank wells resulting
in ΔFluorescence. The relative number of viable cells
was expressed as percentage of untreated cells and cal-
culated as 100 x ΔFluorescence (treated cells)/ΔFluores-
cence (untreated cells).Flow cytometric analysis of apoptosis
U-266-1970 cells were incubated with 20 U/mL IL-6
alone or in combination with 1000 U/ml IFN-γ, and/or
agonistic Fas-antibody CH-11 (100 ng/mL:, Immuno-
tech, Marseilles, France) and/or isotype specific control
IgM (X-0942, 100 ng/mL, DAKO A/S, Glostrup, Den-
mark). The percentage of Annexin V-positive/PI-
negative apoptotic cells was measured on a FACScan
flow cytometer and analyzed with CellQuest software
(Becton Dickinson, San José, CA, USA), using the
Annexin V-FITC kit (Calbiochem) or, when analyzing
EGFP-transfected cells, with the Annexin V, Alexa Fluor
Figure 1 Protein expression of Stat1, P-Stat1 and FLAG in transfected cells. (A) U3A cells were transiently transfected with the pcIneo
vector, the wtStat1pcIneo vector and the Stat1C vector as indicated. The cells were left untreated or were treated with IFN-γ (1000 U/mL) for 24
hours. The cells were lysed and Western blot analysis was performed using the indicated antibodies. (B) and (C) Stably transfected U-266-1970
cells were left untreated or were treated with IFN-γ (1000 U/mL) for the indicated times. Protein lysates were prepared and Western blot analysis
was performed using the indicated antibodies.
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Fluorometric Microculture Cytotoxicity Assay (FMCA)
The FMCA is an automated assay that measures fluores-
cence generated from hydrolysis of fluorescein diacetate
to fluorescein by cells with intact plasma membranes
[34]. In this assay, the sensitivity to drugs is determined
by calculating a survival index (SI%), defined as the 100 x
ΔFluorescence (treated cells)/ΔFluorescence (untreated
cells), which is proportional to the number of living cells.
Cell cultures were seeded in drug-prepared plates up in
384 well plates at a density of 10 000 cells/ well and trea-
ted as described elsewhere [35]. The drugs used in the
assay were etoposide, SAHA, dexamethasone, doxorubi-
cin, As203, bortezomib, irinotecan, amsacrine, partheno-
lide, fludarabine, IMD 0354, 17-AAG/geldanamycin, TBB,
docetaxel, oncovin, and resveratrol. For each drug, fivedifferent concentrations were used. For each drug, IC50-
values (inhibitory concentration 50%) were calculated by
using non-linear regression and a standard sigmoidal
dose–response model in the GraphPadPrism program
(GraphPad Software, Inc. San Diego, CA, USA). The
FMCA assay was also used to screen the Library of
pharmacologically active compounds (LOPAC1280)
(Sigma-Aldrich, St. Louis, Mo.) consisting of 1266 drugs
from 56 pharmacological classes and the Spectrum Col-
lection (MicroSource Discovery Inc., Groton, Conn.) con-
sisting of 2000 drug components, natural products and
bioactive components. All the LOPAC drugs were
screened at a concentration of 10 μM. An Accord HTS
database (Accelrys Inc, San Diego, CA, USA) and Small
Laboratory Information and Management System (SLIMS:
Kelley, Lunn, Stockwell 2004) were used for screening
data management and analysis. Raw data files were loaded
into the SLIMS software which calculates percent
Figure 2 Nuclear translocation and transcriptional activity of
stably transfected cells. Stably transfected U-266-1970-pcIneo cells
and U-266-1970-Stat1C cells were left un-treated or were treated
with 1000 U/mL IFN-γ for 0.5 hours. Nuclear and cytoplasmic protein
extracts were prepared. (A) Western blot analysis of the nuclear (n)
and cytoplasmic (c) protein extracts were performed using the
indicated antibodies. The proteins α-tubulin and α-histone H3 are
markers for the cytoplasmic and nuclear fraction respectively. (B)
Stably transfected U-266-1970-pcIneo or U-266-1970-Stat1C cells
were left untreated or were treated with IFN-γ (1000 U/mL) for the
indicated times. Protein lysates were prepared and Western blot
analysis was performed using the indicated antibodies. (C) The
luciferase reporter contruct GBP-luc was cotransfected with hubactp/
lacZ vector into U-266-1970-pcIneo cells and U-266-1970-Stat1C cells
as described. After 24 hours of treatment with IFN-γ (1000 U/mL),
protein extracts were prepared and luciferase assays were
performed. The graph shows fold induction of relative light units
(RLU) as the mean of three independent experiments ± SD.
Corrections have been made for varying transfection efficiency.
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Results
Establishment of U-266-1970 cells sublines with a stable
expression of Stat1C
With the aim of evaluating the role of constitutive tran-
scriptional activity and expression of Stat1, we estab-
lished sublines of U-266-1970 cells expressing wild type
Stat1 or the active mutant Stat1C [23], where the Ala-
656 and Asn-658 in the SH2-domain have been
exchanged for cysteine to promote spontaneous
dimerization and constitutive activation of the Stat1C
protein. Besides the activating mutation, the Stat1C
vector also offers the advantage of a FLAG-tag in its C-
terminus, enabling discrimination between the trans-
fected gene and endogenous Stat1 protein. Transfection
of Stat1-deficient U3A-cells with vectors expressing
wtStat or Stat1C restored Stat1 expression (Figure 1A).
Also, IFN-γ treatment induced Stat1 phosphorylation in
the Stat1C mutant. U-266-1970 MM cells were stably
transfected with wtStat1pcineo, Stat1C, and empty vec-
tor pcIneo, respectively, and G418-resistant cells were
collected after 6–10 weeks. The expression of wtStat1p-
cineo and empty vector pcIneo was confirmed by PCR,
using primers specific for the vector sequence (data not
shown). The expression of the Stat1C vector FLAG-tag
protein was confirmed by Western blot (Figure 1B).
To evaluate Stat protein expression and activation in the
different sublines (designated U-266-1970-wtStat1pcIneo
(data not shown), U-266-1970-Stat1C, and U-266-1970
-pcIneo), we stimulated the cells with IFN-γ and har-
vested them at the indicated time points. Stat1C-
transfected cells displayed a pronounced increase in
Stat1 expression and a marked enhancement of IFN-γ
induced tyrosine phosphorylation (Figure 1C). The U-
266-1970-Stat1C subline was chosen for further analysis
outlining the role of Stat1 on gene expression and apop-
tosis sensitization.
Nuclear translocation of Stat1C and increased
transcriptional activity in U-266-1970-Stat1C cells
To confirm the constitutive transcriptional activity of
the transfected Stat1C protein we evaluated the potential
of Stat1C to translocate to the nucleus in untreated cells
and in response to IFN-γ stimulation. U-266-1970
-Stat1C and U-266-1970-pcIneo cells were treated with
IFN-γ at the indicated times, the cells were harvested
and nuclear and cytoplasmic protein lysates were pre-
pared and compared to untreated control cells. As
depicted in Figure 2A, in U-266-1970-Stat1C cells, the
FLAG protein was present in both the cytoplasmic and
the nuclear fraction of stimulated and un-stimulated
cells. The results show that transfected Stat1C
Figure 3 MLPA Apoptosis gene expression profile of U-266-1970-pcIneo cells and U-266-1970-Stat1C cells. The cells were left untreated
or were treated with IFN-γ for 6 hours as indicated, RNA lysates were prepared and subjected to MLPA analysis as described. Average relative
gene expression from three independent experiments performed in duplicates, are displayed (one pcIneo-sample and one Stat1C-sample were
lost). The relative mRNA gene expression is color coded from green (no expression) to red (highest expression) (see bar at the top). The MLPA
probes are indicated on the right. All genes that differed more than 2x between empty-vector-transfected and Stat1C-expressing sub-lines are
summarized in Table 1.
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induced tyrosine phosphorylation, thereby suggesting
that the protein has the potential to influence gene tran-
scription constitutively. Upon IFN-γ stimulation,phosphorylated Stat1 was present in both the cytoplas-
mic and the nuclear fraction of both sublines.
To confirm that the nuclear presence of Stat1C in the
U-266-1970-Stat1C sub-line was reflected by an





in Stat1C vs pcIneo
Fold expression in Stat1C/IFN-γ
vs pcIneo/IFN-γ
PMAIP1-RO1 Noxa Bcl-2 family 4.4 5.6
BH3-only
Pro-apoptotic
HRK-R01 Harakiri Bcl-2 family 9.1 28.5
BH3-only
Pro-apoptotic
MCL1-R02 Mcl-1 short Bcl-2 family 11.2 13.4
Bax-like
Pro-apoptotic
BCLG-R01 Bcl-GS Bcl-2 family n.s. 2.8
Bax-like
Pro-apoptotic
(P< 0.005, > 2-fold difference).
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analyzed the protein expression of the well-characterized
IFN-inducible gene interferon regulatory factor 1 (IRF-1)
in the sublines. Figure 2B shows that both the basal ex-
pression and the IFN-γ induced expression of IRF-1
were significantly increased in the Stat1C transfected
subline (see also Additional file 1: Figure S1). Consistent
with increased Stat1 activity we also observed a statisti-
cally significant (>2-fold) higher transcription from
GBP-luc, a luciferase reporter containing Stat1-inducible
ISRE and GAS elements, in Stat1C expressing U-266-
1970 cells as compared to untreated control cells
(Figure 2C). As expected, the increase in transcriptional
activity was further enhanced by the treatment of IFN-γ
in both U-266-1970-Stat1C and U-266-1970-pcIneo
cells.
Regulation of apoptosis-related genes in
U-266-1970-Stat1C cells
Next, we examined how the constitutively active Stat1
would influence the expression of apoptosis-related
genes in MM. For this purpose, we used the SALSA
P011 Apoptosis mRNA Multiplex Ligation-Dependent
Probe Amplification Assay (MLPA) kit. This assay quan-
tifies the relative mRNA expression of 39 different
probes corresponding to apoptosis-related genes, includ-
ing 21 different Bcl-2 family genes, 7 members of the
IAP family, and other pro- and anti-apoptotic proteins
such as Apaf-1, Smac/DIABLO, and Flip. Figure 3 illus-
trates the gene expression of un-stimulated and IFN-γ-
stimulated U-266-1970-pcIneo cells and U-266-1970-
Stat1C cells. We considered a difference in gene expres-
sion to be significant if quantified to be at least two-fold,in addition to being statistically significant as calculated
by the Student’s t-test. Genes that differed significantly
according to these criteria are summarized in Table 1.
Notably, Stat1C expression was associated with
increased mRNA levels of Harakiri, the short form of
Mcl-1 and Noxa genes. Accordingly, Noxa protein ex-
pression was increased in the Stat1C cells as shown by
Western blot analysis (Figure 4A). The protein expres-
sion of Harakiri, a small protein that is notoriously diffi-
cult to detect by Western blotting, could not be assayed
(results not shown).
The MLPA analysis did not reveal a regulation of the
Bcl-2 and Bcl-XL genes at the transcriptional level.
However, given the previously established link between
these proteins, Stat activation and survival [6,18], we
were interested in whether the level of Bcl-2 and Bcl-XL
protein expression would differ between the U-266-
Stat1C cell line and the vector transfected subline. In
addition to these genes, the protein expression of Mcl-1
was assayed, the short form of Mcl-1 being the gene
most consistently up-regulated at the mRNA level in the
Stat1C subline. As shown in Figure 4B, the Bcl-2, Bcl-XL
and Mcl-1 were, however, not significantly different at
the protein expression level in the U-266-1970-Stat1C
sub-line. IFN-γ stimulation did not have any major effect
on the protein expression of any of the genes examined
(see also Additional file 1: Figure S2).
Stat1 activation attenuates IL-6 induced Stat3 activity in
U-266-1970 cells
We have previously shown that in addition to activating
Stat1, IFN-γ also deactivates Stat3 [22]. We hypothesized
that Stat1 activation has a negative effect on Stat3
Figure 4 Protein expression of Mcl-1, Bcl-XL, Bcl-2 and Noxa in U-266-1970-pcIneo cells and U-266-1970-Stat1C cells. (A) and (B) U-266-
1970-pcIneo cells and U-266-1970-Stat1C cells were left untreated or were treated with IFN-γ (1000 U/mL) for the indicated times. Protein lysates
were prepared and Western blot analysis was performed using the indicated antibodies.
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Stat3 and thereby augmenting apoptosis sensitivity. Fig-
ure 5 shows Western blots of untreated and IL-6 treated
U-266-1970-pcineo cells and U-266-1970-Stat1C cells.
Stat3 was examined after IL-6-induction in IL-6
deprived U-266-1970-pcIneo and U-266-1970-Stat1C
cells at 6 and 24 hours. In support of our hypothesis, the
level of phosphorylated Stat3 in response to IL-6-
stimulation at 6 and 24 hours were attenuated in the
U-266-1970-Stat1C subline as compared to U-266-1970-
pcIneo cells. As depicted the levels of total Stat3 protein
were unaltered in U-266-1970-Stat1C cells as compared
to U-266-1970-pcIneo cells (see also Additional file 1:
Figure S3).The effect of Stat1 on the sensitivity to Fas-induced
apoptosis in MM cells
Our previous studies have shown that IFN-γ sensitizes
myeloma cells for apoptosis by the death receptor Fas
[21]. To evaluate whether the constitutive activation of
Stat1 would render the cells more sensitive to Fas-induced
apoptosis, we stimulated the Stat1C expressing subline
and the U-266-1970-pcIneo cells with the Fas receptor ag-
onistic antibody, with or without prior IFN-γ -stimulation.
The proportion of apoptotic, Annexin V positive and pro-
pidium iodide negative cells were determined by flow
cytometry as described. As depicted in Figure 6, stimula-
tion with IFN-γ prior to Fas-exposure increased the per-
centage of apoptotic cells in the U-266-1970-pcIneo
Figure 5 Protein expression of Stat3 and pStat3 in
U-266-1970-pcIneo cells and U-266-1970-Stat1C cells.
U-266-1970-pcIneo cells and U-266-1970-Stat1C cells were left
untreated or were treated with IL-6 (20 U/mL) for the indicated
times. The cells were IL-6-deprived overnight prior to stimulation
and harvest. Protein lysates were prepared and Western blot analysis
was performed using the indicated antibodies.
Figure 6 Stat1C alone does not confer sensitivity to
Fas-induced apoptosis. U-266-1970 cells and U-266-1970-Stat1C
cells were left untreated or were treated with IFN-γ (1000 U/ml) as
indicated for 96 hours, followed by a 24 hour incubation with
agonistic Fas-antibody CH-11 (FAS) as indicated. The percentage of
Annexin V-positive/PI-negative apoptotic cells was evaluated by flow
cytometry as described in Materials and Methods. The graph shows
the percentage of AnnexinV positive, PI-negative cells, i.e. early
apoptotic cells, as a mean of three experiments ± SD.
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The sensitizing effect of IFN-γ was sustained in the U-
266-1970-Stat1C cells. Importantly, transcriptionally ac-
tive Stat1 alone did not significantly enhance the apoptotic
response to Fas in the absence of IFN. Confirming our
previous findings, stimulation with IFN-γ prior to Fas-
exposure increased expression of Fas receptor in both
sublines [22] (See Additional file 1: Figure S4). These data
suggests that activation of Stat1 per se is not sufficient to
significantly sensitize U-266-1970 cells to Fas-induced
apoptosis in the absence of IFN-γ stimulation, indicating
that the effect of IFN-γ on Fas-induced apoptosis is not
solely mediated by Stat1 activation.
The effect of Stat1 on drug sensitivity in MM cells
To determine if transcriptionally active Stat1 affects
the sensitivity to apoptosis in general, we selected 16
different drugs on the basis of MM therapeutic rele-
vance, previously established connection to Stat1 or
Stat3 activation, and/or novelty, and tested the survival
index of each drug in a broad concentration range
using the FMCA assay. The responses to six of these
drugs (Etoposide, IMD 0354, Fludarabine, As2O3, Bor-
tezomib, and SAHA) are graphed in Figure 7. There
was no significant difference between the U-266-1970
-Stat1C sub-line and the vector transfected control
cells in the sensitivity to the drugs tested (Figure 7
and data not shown).
In an unbiased high throughput screening, we
exposed the sublines to the 1266 drugs of the LOPAC
library and to the 2000 pharmacologically active sub-
stances of the Spectrum Collection library. Only 18 of
the drugs of the LOPAC induced a survival index lower
than 50% at a concentration of 10 μM in any of the
sub lines (data not shown), confirming the fact that
myeloma cells are highly resistant to apoptosis. We ar-
bitrarily considered 20% of difference in survival index
between empty-vector transfected and Stat1-transfected
sub-lines to be a potentially relevant difference. Several
drugs induced a differential response in the cell lines
using this criterium, but when repeating the experi-
ments on a smaller scale using resazurin assay, only 2
drugs (gitoxin and gitoxigenin) could be confirmed as
yielding statistically significant changes in apoptosis
sensitivity in the two cell lines, the Stat1 expressing
cells being more resistant than control cells (Additional
file 1: Figure S5).
Discussion
An important challenge in MM research lies in pinpoint-
ing the critical factors that regulate growth and survival
so that potential therapeutic targets can be defined. Stat1
is constitutively activated in many MM patients [6], and
has been described as a pro-apoptotic protein in a
Figure 7 Dose–response curves displaying the sensitivity of U-266-1970-pcIneo cells and U-266-1970-Stat1C cells to different drugs.
Using the FMCA assay as described, the response to indicated concentrations of (A) Etoposide, (B) IMD 0354, (C) Fludarabine, (D) As2O3, (E)
Bortezomib, (F) SAHA, in U-266-1970-pcIneo cells and U-266-1970-Stat1C cells was monitored. Each data point represents the mean of three
independent experiments ± SD.
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ber Stat3, has been identified as a pro-survival protein
activated downstream the MM growth- and survival fac-
tor IL-6 [6,7,36,37] and as a promising drug target
[19,20]. Both proteins can be regulated by IL-6 and by
interferons, they can bind to the same DNA motifs, they
are highly homologous to each other, and they can form
heterodimers of Stat1/Stat3 that may have other specifi-
cities in gene regulation as compared to either homodi-
mer alone [38]. It has also been suggested that Stat1 and
Stat3 can oppose the effects of each other [16,39-41], for
instance by exerting opposing effects on the promoters
of pro- or antiapoptotic genes [18].
We have previously found that IFN-γ sensitizes MM
cells for apoptosis induced by the death receptor Fas [21]
by a mechanism involving up-regulation of the Fas recep-
tor [22]. Intriguingly, we found that IFN-γ stimulationinduces not only Stat1 activation but also Stat3 deactiva-
tion [22]. In the present study we show that Stat3 protein
was decreased and phosphorylation of Stat3 was attenu-
ated in an IL-6 dependent MM cell line, the U-266-1970 ,
expressing a constitutively active mutant of Stat1, the
Stat1C. This observation is in line with other studies that
have shown enhanced Stat3 expression and activation in
Stat1 null cells [16] and, conversely, enhanced Stat1 ex-
pression and activation in Stat-3 null cells [17]. It is also
consistent with the finding that IFN-α induced apoptosis
of MM cells is associated with inhibition of Stat3 activity
[42]. Since Stat1 and Stat3 are often expressed simultan-
eously in the same tumor cells, it has been suggested that
one protein dominates over the other in the influence on
survival, depending on e.g. the durability of activation of
each protein [43]. The Stat1C protein would be expected
to function qualitatively as endogenous Stat1 and becomes
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treatment [23] although it is constitutively present in the
nucleus also in the absence of IFN treatment. In the
present study we show that Stat1C- expressing cells with
constitutive transcriptional activity were sensitized to Fas
induced apoptosis by IFN-γ, but that apoptosis induced by
the Fas receptor alone was not enhanced in Stat1C-
expressing cells as compared to empty vector-transfected
cells. This data is consistent with our previous findings
[21,22], but suggests that Stat1 up-regulation is not a sole
mediator of the apoptosis sensitizing effect of IFN-γ.
We found that the expression of Stat1C influenced the
expression of the apoptosis-related gene Mcl-1 s, while
the expression of Bcl-2 and Bcl-xL was not significantly
altered in the Stat1C sub-line. Mcl-1 s has previously
been characterized as important regulators of survival in
MM and interesting therapeutic targets [44,45]. Harakiri,
a pro-apoptotic member of the Bcl-2 family, was also
up-regulated in the Stat1C-expressing sub-line. This
protein interacts specifically with Bcl-2 and Bcl-XL,
counteracting their anti-apoptotic effect [46]. The
mRNA expression of the pro-apoptotic Bcl-2 protein
Noxa was strongly augmented in U-266-1970-Stat1C.
Interestingly, Noxa has previously been shown to be
down-regulated in Stat1 (−/−) cells [47]. Its expression
has been associated with, amongst others, p53-mediated
apoptotic response [48].
Despite the up-regulation of the pro-apoptotic pro-
teins, introduction of the Stat1C mutant in MM cells
did not affect apoptosis in response to any of the 16
drugs selected on the basis of relevance for MM therapy,
known Stat1 or Stat3 influence, or novelty. In the HTS
of drugs from the LOPAC library and the Spectrum col-
lection we did not observe a general Stat1-dependent
difference in apoptosis-sensitivity. However, we could
confirm that Stat1C-expressing MM cells were signifi-
cantly more resistant in response to two similar com-
pounds – gitoxin and gitoxigenin. A major role of Stat1
in promoting apoptosis have previously been challenged
by studies showing increased Stat1 expression in cells
with acquired resistance to chemotherapeutic drugs and
radiation [49,50]. At present the mechanism(s) for these
observations are unknown, but may involve other part-
ners of Stat1 i.e. the ISGF3 (Stat1/Stat2/IRF9 complex)
mediated signaling [49,50].
Conclusions
We conclude that constitutive transcriptional activation
of Stat1 alters IL-6 induced activation by Stat3. However,
this shift alone is not sufficient to alter sensitivity to
apoptosis induced by Fas receptor or sensitivity to thera-
peutic drugs in MM. This study suggests that also Stat1
independent pathways are operative in IFN mediated
apoptosis sensitization and underlines the importance ofunderstanding the details of MM survival pathways in
order to exploit them as therapeutic targets.
Additional file
Additional file 1: Figure S1. (A) U-266-1970-pCIneo and
U-266-1970-Stat1C were induced by IFN-γ (1000U/mL) for the indicated
times. Quantification of w.b. for independent biological replicates (n = 3).
A representative experiment is depicted in Figure 2B. Expression of IRF-1
relative to Actin ± S.D. is shown. * p-value< 0.024. Figure S2. U-266-1970
-pCIneo and U-266-1970-Stat1C were induced by IFN-γ (1000U/mL) for
the indicated times. Quantification of w.b. for independent biological
replicates (n = 3). A representative experiment is depicted in Figure 4B.
Expression of MCL-1, BCL-2 and BCL-XL relative to Actin ± S.D. is shown.
Figure S3. Quantification of the w.b. shown in Figure 5. (A) phospho-
Stat3 expression in U-266-pCIneo and U-266-Stat1C treated with IL-6
(20U/mL) for 6 and 24 hours, and (B) showing total Stat3 expression for
the same experiment. Figure S4. U-266-1970-pCIneo and U-266-1970
-Stat1C were induced by IFN-γ (1000U/mL) for 96 h. Apoptosis was
induced as shown in Figure 6. Expression of CD95/Fas analysed by Flow
cytometry analysis (n = 3) is indicated as mean flourescense intensity
(MFI). Figure S5. Response to Gitoxin and Gitoxigenin at 72 h in U-266-
1970-pcIneo cells and U-266-1970-Stat1C cells using the Resazurin assay.
Each data point represents the mean of three independent
experiments ± SD.
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